Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.

Taro IguchiGo KimuraSatoshi FukasawaHiroyoshi SuzukiHiroji UemuraKazuo NishimuraHiroaki MatsumotoAkira YokomizoAndrew J ArmstrongBrad RosbrookJennifer SuggBenoit BaronLucy ChenFutoshi KuniedaArnulf Stenzl

Published in: International journal of urology : official journal of the Japanese Urological Association (2021)

Enzalutamide plus androgen deprivation therapy has clinical benefit with a tolerable safety profile in Japanese men with metastatic hormone-sensitive prostate cancer, consistent with the overall population.

Keyphrases

prostate cancer
phase iii
radical prostatectomy
squamous cell carcinoma
small cell lung cancer
open label
clinical trial
middle aged
stem cells
double blind
randomized controlled trial
cell therapy
mesenchymal stem cells